Relay Therapeutics (RLAY) EBIT Margin (2021 - 2026)
Relay Therapeutics (RLAY) posted quarterly EBIT Margin of 2619.67% for Q1 2026, down 151446.0% year-over-year from N/an in Q1 2025, and down 202.45% quarter-over-quarter from 866.14% in Q4 2025.
Relay Therapeutics (RLAY) EBIT Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported EBIT Margin for 6 consecutive years, with 2619.67% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin fell 151446.0% year-over-year to 2619.67%; the TTM figure through Mar 2026 stood at 2776.6% (up 200233.0% YoY), while the FY2025 annual figure was 1971.59%, up 175048.0% from the prior year.
- EBIT Margin declined to 2619.67% in Q1 2026 per RLAY's latest filing, from 866.14% in the prior quarter.
- Across five years, EBIT Margin topped out at 9219600.0% in Q4 2023 and bottomed at 89117.65% in Q2 2023.
- Historically, EBIT Margin has averaged 690655.84% across 5 years, with a median of 11351.11% in 2025.
- On a YoY basis, EBIT Margin climbed as much as 924839486 bps in 2023 and fell as far as 6779956 bps in 2023.
- Relay Therapeutics' EBIT Margin stood at 28794.86% in 2022, then jumped by 32118 bps to 9219600.0% in 2023, then sank by 100 bps to 903.0% in 2024, then gained by 4 bps to 866.14% in 2025, then slumped by 202 bps to 2619.67% in 2026.
- Business Quant data shows RLAY's EBIT Margin at 2619.67% in Q1 2026, 866.14% in Q4 2025, and 11351.11% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -25,949.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25,949.71% |
| Mar 31, 2026 | -2,619.67% |
| Dec 31, 2025 | -866.14% |
| Jun 30, 2025 | -11,351.11% |
| Mar 31, 2025 | -1,105.21% |
| Mar 31, 2024 | -903.00% |
| Dec 31, 2023 | 9,219,600.00% |
| Sep 30, 2023 | -291.95% |
| Jun 30, 2023 | -89,117.65% |
| Mar 31, 2023 | -44,768.58% |
| Dec 31, 2022 | -28,794.86% |
| Sep 30, 2022 | -24,968.60% |
| Jun 30, 2022 | -21,318.08% |
| Mar 31, 2022 | -14,969.21% |
| Dec 31, 2021 | -11,944.09% |
| Sep 30, 2021 | -9,157.66% |
| Jun 30, 2021 | -22,936.02% |
| Mar 31, 2021 | -4,454.31% |